Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Genitourinary 1

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1Neoplasms 1

Interventions

Dexamethasone 33Lenalidomide 14pomalidomide 12daratumumab 12Bortezomib 12venetoclax 7Cyclophosphamide 7isatuximab 6Therapeutics 6trametinib 4carfilzomib 4Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3fludarabine 3dabrafenib 3Vemurafenib 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Drug Therapy 3Denosumab 3Ciprofloxacin 3Calcium Dobesilate 3ridaforolimus 2pembrolizumab 2molibresib 2liposomal amphotericin B 2fludarabine phosphate 2cobimetinib 2afuresertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Introns × Plasma cell × Clear all
NCT00083551 2015-11-23

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

University of Arkansas

Phase 3 Completed
668 enrolled 7 charts
Plasma cell

Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡